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ABSTRACT 
 
 Tissue expansion is the process by which extra skin is generated using a device that applies 
pressure from underneath the skin. Over the course of weeks to months, stretching by this 
pressure creates a flap of extra tissue that can be used to cover a defect area or enclose a 
permanent implant. Conventional tissue expanders require a silicone shell inflated either by 
external injections of saline solution or air, or by internal osmotic pressure generated by a 
hydrophilic polymer. In this study, a shell-free tissue expander comprised only of a chemically 
cross-linked biocompatible polymeric hydrogel is developed. The cross-linked network of 
hydrophilic polymer provides for intrinsically controlled swelling in the absence of an external 
membrane. The new type of hydrogel expanders were characterized in vitro as well as in vivo 
using a rat-skin animal model. It was found that increasing the hydrophobic polyester content in 
the hydrogel reduced the swelling velocity to a rate and volume that eliminate the danger of 
premature swelling rupturing the sutured area. Additionally, increasing the crosslinking density 
resulted in enough mechanical strength of the hydrogel to allow for complete post-swelling 
removal, without the hydrogel cracking or crumbling. No systemic toxicity was noted with the 
expanders and histology showed the material to be highly biocompatible. These expanders have 
an advantage of tissue expansion without requiring an external silicone membrane, and thus, they 
can be cut or reshaped at the time of implantation for applications in small or physically 
constrained regions of the body.  
 
Keywords: Tissue expander, cross-linked hydrogels, reshapable, poly(ethylene glycol) 
diacrylate, poly(lactic-co-glycolic acid), PLGA-PEG-PLGA   
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1. Introduction 
   
 Tissue expanders are an important tool for generating extra skin for use in reconstructive 
surgery. Tissue expanders have a long history of successful use in clinical applications, dating 
back to 1957, to expand skin and support tissues by applying pressure underneath the dermis [1-
4]. When a part of the human body is lost or damaged, tissue expanders are used to increase the 
amount of soft tissue in preparation for replacement of tissues lost [5]. For example, a tissue 
expander can be used to increase the oral mucosa for a significantly more predictable bone graft, 
developing for a subsequent dental implant. Moreover, new tissue created by a tissue expander 
may be used for subsequent reconstructive surgical procedures, such as inserting a breast 
prosthesis following mastectomy, or replacing skin lost to a burn. Tissue expanders are often 
used in various locations including the chest wall, head, neck, shoulder, arm, ear, finger, hairline, 
lower-back, groin, calf and foot regions [6-12].  
 
 Currently, the majority of tissue expanders are essentially silicone elastomer balloons 
surgically placed under the skin and inflated over the course of several weeks of healing. This 
inflation is usually done by injecting sterile saline into the balloon.  Finding portals for this 
periodic fluid injection is difficult, time-consuming, and the process is painful for the patient. 
The overall design of expanders has changed little over the years. Most tissue expanders are 
basically subcutaneous bags that are externally inflated at timed intervals [13-16]. There are 
significant drawbacks to this design, especially the need of multiple injections and interventions 
into the same location can increase the risk of infection or hemorrhage [17]. The use of inflatable 
balloons also sets a lower limit on the size or shape of expanders.  
 
 “Self-swelling” Hydrogel tissue expanders provide a way to avoid this periodic injection of 
fluid for expansion.  Several hydrogel tissue expanders have already been developed. All of 
them, however, are enclosed inside a silicone rubber shell to control the rate of expansion and to 
avoid tearing the wound within the first weeks following surgical placement [18-24]. The 
presence of a silicone rubber shell restricts the application of commercial hydrogel expanders to 
a limited number of sizes and shapes.  Due to this limitation, hydrogel tissue expanders have not 
been applied for applications which require small expanders of exact size for specific locations 
[25]. The purpose of this research is to develop a self-swelling, hydrogel tissue expander that can 
be reshaped using scissors or a knife at the time of emplacement by a surgeon.  This self-
swelling and reshapable tissue expander can overcome problems associated with current 
technology by eliminating exterior equipment and allowing custom fitting of the expander to the 
tissue by the surgeon.  
 
 Poly(lactide-co-glycolide) (PLGA) is a hydrophobic, biodegradable polyester which has been 
used for decades both in mechanical applications, such as sutures [26], and a wide variety of 
drug-delivery applications [27]. PLGA naturally hydrolyzes to non-toxic components, lactic acid 
and glycolic acid [28]. Poly(ethylene glycol) (PEG) is a non-degradable, hydrophilic polyether 
which has good biocompatibility, as it elicits little immune response [29]. PLGA and PEG were 
utilized to prepare hydrogels with controllable swelling properties. The swelling of the non-
degradable, hydrophilic PEG is modified by the hydrolysis rate of degradable PLGA so that the 
swelling of the entire structure can be controlled. 
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 This study investigates a new shell-free, reshapable hydrogel by in vitro and in vivo testing. 
This device is designed to expand skin at a controlled rate without over-expansion that may 
cause eruption through the incision or ischemia and necrosis of overlying tissue. Furthermore, it 
is desirable for such an expander to be reshaped at the time of emplacement to match the void 
size and shape. This would allow for tissue expansion in tight or constrained regions where 
traditional expanders do not fit. 
 
2. Materials and methods 
 
2.1. Materials 
 
 Acryloyl chloride (AAc), triethylamine (TEA), poly(ethylene glycol) diacrylate (PEGDA), 
ethylene glycol dimethacrylate (EGDMA), azobisisobutyronitrile (AIBN), and stannous octoate 
(SnOct) were obtained from Sigma Aldrich. SnOct was purified by vacuum distillation prior to 
usage. AIBN was purified by recrystallization from methanol and stored frozen. Triethylamine 
(TEA) was vacuum distilled and stored over KOH. Dichloromethane (DCM) and hexane were 
obtained from Malinckrodt. Poly(lactic-co-glycolic acid) (PLGA, Cat.No. RG503H) was 
obtained from Boeinger Ingelheim. Other reagents were of analytical quality and used as 
received. 
 
2.2. Synthesis and characterization of tissue expander polymers 
 
 Triblock PLGA-PEG-PLGA diacrylate was synthesized as previously described [30-32]. 
Briefly, a PEG-diol of required molecular weight was obtained commercially (Sigma Aldrich) 
and dried under deep vacuum in a round bottom flask with stirring at 150 °C for 4 hours to 
remove water. The dehydrated PEG-diol was back-flushed with inert argon and DL-lactide and 
glycolide monomers were added to the PEG. As a catalyst, SnOct dissolved 10% w/v in toluene 
was added in a ratio of 1/200 mole catalyst/monomers.  These were placed under a deep vacuum 
for 0.5 hour, sealed off, and then heated to 150 °C for 8 hours.   
  
 PLGA-PEG-PLGA with a wide variety of block sizes was generated using this method by 
controlling monomer to initiator ratio. The alcohol endcaps of the PEG-diol serve as the initiator 
of this system. As such, the molar ratio of PLGA monomers to PEG block controls the relative 
molecular weights of the resultant PLGA-PEG-PLGA block copolymer. For example, PLGA-
PEG-PLGA (5000-1000-5000 Da, 50:50 lactide:glycolide (L:G)) was obtained by reacting 10 
grams of PEG diol (1000 Da, 0.01 moles) with 55.4 g DL-lactide (0.38 moles) and 44.6 g 
glycolide (0.38 moles) catalyzed by 15.6 ml of 10% SnOct/toluene. By carefully selecting 
reaction feed ratios, the resultant triblock block weight could be controlled [33]. Additionally, 
PLA and PLGA dialcohol polymers were generated by replacing the PEG block with 1,10-
decanediol and performing the same reaction without the initial dehydration step [34]. After 
synthesis, the crude polymer was dissolved in a small amount of dichloromethane, filtered and 
reprecipitated in a mixture of hexane:ethanol (80:20). The resulting filtrate was vacuum dried to 
obtain the purified PLGA-PEG-PLGA, poly(lactic acid)-diol (PLA-diol), or PLGA-diol product 
[35].  
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 The polymers were then vinyl activated by acryloyl chloride, converting them to macromers 
[36, 37]. For this process, the polymer was dissolved in anhydrous DCM with stirring. A 3X 
molar equivalent, to hydroxyl units, of triethylamine and acryloyl chloride was added to the 
stirring reaction solution at room temperature. Due to acryloyl chloride’s rapid degradation in the 
presence of water, care was taken to avoid moisture during this process. Due to the dangers 
associated with acryloyl chloride, the reaction was performed carefully under an externally 
ventilated fume hood. The flask was fitted with a condenser operated by a recirculating chiller 
(Neslab RTE-7, Thermo-Scientific) filled with a 1:1 water:ethylene glycol mixture at -10 °C. 
Atop this, a calcium sulfate (DrieRite) desiccant trap was fitted to prevent backflow of humidity. 
The flask was heated to 80 °C for two hours under these reflux conditions and subsequently 
stirred at room temperature overnight. The resultant acrylated polymer was passed through a 
filter paper to remove triethylamine-HCl and precipitated in an 80:20 hexane:ethanol mixture. 
Subsequently, it was further purified to remove residual acrylic acid which is poorly removed by 
conventional precipitation. For this, the polymer was dissolved in dichloromethane and dialyzed 
against acetonitrile using a regenerated cellulose dialysis membrane (Spectrapor) with a 
molecular weight cutoff below that of the macromer. Alternatively, the polymer dissolved in 
ethyl acetate was mixed overnight with activated carbon and filtered. After either of these 
processes, the purified polymer solution was reduced under vacuum, redissolved in DCM and 
precipitated once more in 80:20 hexane:ethanol mix. 
 
 The polymers were characterized by gel-permeation chromatography (GPC) and proton 
nuclear magnetic resonance (NMR) spectroscopy. NMR was performed in deuterated chloroform 
on a 500 MHz instrument by Purdue Interdepartmental NMR Faculty. Fourier-transform infrared 
spectrophotometry (FTIR) was performed using a Thermo-Matsen Satellite IR system. GPC was 
performed with DCM as the mobile phase, 1 ml/min against a series of 3 GPC columns (7.8 x 
300 mm, mixed porosities) using polystyrene standards (Agilent EasiCal™ standards) to 
generate a standard curve. This size assay was performed with either a Varian Prostar HPLC 
system with UV/Vis detection at 235 nm or with a Waters Breeze-2 HPLC system with detection 
by refractive index.  
 
 The purified, vinyl- functionalized macromers were dissolved in anhydrous DMSO. 
Commercially available macromers, such as PEGDA, and short-chain crosslinkers, such as 
EGMA, were added in DMSO solution for a total concentration of 10-30% weight per volume 
(formulations shown in Table 1). AIBN was added to an approximate concentration of 0.04% 
(w/v) and the solution was degassed by lightly bubbling with argon or difluoroethane. The 
resulting combined solution was sealed in a microcentrifuge tube and heated to 65 °C overnight 
to crosslink. The following day, the microcentrifuge tube top was opened and the bottom was 
punctured. Compressed difluoroethane applied to the puncture gently pushed the hydrogel out of 
the microcentrifuge tube. The reshapable hydrogel was soaked for two to three days with shaking 
in excess ethyl acetate, then soaked in excess ethanol for two to three days to wash away any un-
crosslinked components. Marked deswelling of the hydrogel occurred during soaking in solvent-
free ethanol. The reshapable hydrogels were then dried under deep vacuum for a week to remove 
solvents. 
 
 Prior to animal experiments, the reshapable hydrogels were sterilized by exposure to ethylene 
oxide gas either at 54 °C for 16 hours in an Axis AX-60 sterilizer or at room temperature for 24 
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hours in an Andersen sterilizer. Preliminary tests showed that sterilization by -irradiation 
resulted in a marked decrease in flexibility and in control of swelling (data not shown). This is in 
accordance with previous results for -sterilization of biodegradable systems found by other 
researchers. -irradiation induces a variety of crosslinking and fragmentation reactions within the 
polymer matrix that alter its properties [38-41].  
 
2.3. In vitro Swelling Profile 
 
 The hydrogels were shaped by trimming into discs (~3 mm diameter x 2 mm height, dry), 
weighed dry, and placed in well-plates. To each well, an excess of phosphate buffered saline 
(PBS, P4417 tablets from Aldrich mixed with DI water per manufacturer’s instructions) was 
added to soak the hydrogel. The hydrogels were incubated at 37 °C in an orbital agitating shaker 
(MaxQ™ 4450 Benchtop Orbital Shaker, Thermo Fisher Scientific) with agitation at 100 RPM.  
At predetermined time points, the hydrogel was removed, patted dry with lint-free wipes, and 
weighed. The swelling ratio was determined as follows:   
 
𝑄𝑡 =
𝑊𝑡 −𝑊0
𝑊0
 
 
where Qt is the swelling ratio at time t and Wt is the weight of the hydrogel at time t and Wo is the 
weight of the hydrogel at time 0, or the dry hydrogel. The swelling ratio changed over time due 
not only to swelling of the hydrogel, but also to degradation of the polyester blocks. 
 
2.4. Swelling pressure 
 
 Swelling pressure was assayed by placing the reshapable hydrogel disc in a 20 ml 
scintillation vial on top of a heated stage (37 °C) under the probe arm of a texture analyzer 
(TA.XT Plus, Texture Technologies, Inc., Hamilton, MA). The texture analyzer tip (1/2-inch 
Dacron cylinder) was lowered until it touched the hydrogel.  The tip was held still at this position 
while 10 ml of 0.154 M hydrochloric acid (HCl) was added to the vial. HCl was used at an 
isotonic concentration to represent the same salt content as human biological fluids but in 
accelerated degradation conditions for a rapid test. The tip was held still while the reshapable 
hydrogel swelled and the force generated from the swelling of the gel was monitored over 24 
hours.  The maximum swelling force was divided by the swollen expander contact area to obtain 
the swelling pressure. 
 
2.5. Mechanical property of dry hydrogels 
 
 The cross-sectional area of dry hydrogel discs was measured and the discs were loaded onto 
the stage of the TA.XT Plus texture analyzer. Each piece was compressed with a ½-inch radius 
Dacron tip at a crosshead speed of 0.5 mm/sec to 20% strain and held there for 60 seconds and 
then the tip was withdrawn.  The slope of the stress-strain curve from 0-2% strain was measured 
as the elasticity modulus [42]. The compression force at 20% strain after holding for 60 seconds 
was divided by the initial compressive force at 20% strain and converted to percent. This was 
taken as stress relaxation, which is a value related to polymer creep or deformation over time 
[43]. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
2.6. Mechanical strength post-degradation 
 
 Samples which had undergone a swelling assay for 2 months at 37 °C in PBS were used for 
post-degradation mechanical strength. For this test, the swollen sample was removed from the 
well plate and placed on the TA.XTplus platform. It was compressed using a ¼ inch steel ball 
probe at 0.5 mm/sec. The maximum force obtained (in Newtons) was divided by the disc 
thickness (in mm) to obtain a relative strength factor for the reshapable hydrogel samples.  For 
this and other in vitro tests, the results presented represent an average of at least 3 measurements 
unless otherwise specified. 
 
2.7. In vivo analysis 
 
 All work was performed under the auspices of Indiana University School of Medicine 
Institutional Animal Care and Use Committee (IACUC). All animal testing was performed at the 
Laboratory Animal Resource Center (LARC) at Indiana University Medical School (IUMed). 
The reshapable hydrogels selected for animal studies were sterilized and handled aseptically and 
sterile surgical technique was used for all animal implantations. 
 
 Sprague-Dawley rats (~250 gm and 50 days old) were anesthetized by intraperitoneal 
injection of ketamine (100 to 200 mg/kg), and xylazine (5 to 13 mg/kg). A flap of skin and 
subcutaneous tissue above the rat’s skull was reflected. A 3 mm x 2 mm (diameter x height) disc 
of the hydrogel was placed beneath the flap on top of the skull and the wound was closed by 
interrupted sutures (Fig. 1-A).  For tracking of the reshapable hydrogel expansion, each rat head 
was scanned with a 3D scanning Faro arm (FARO, Lake Mary, Florida, USA) three times per 
week with the rats anesthetized by isoflurane (Fig. 1-B). A red line at the bottom of the sutures in 
Fig. 1 is the FaroArm® scan moving across the skin over the placed reshapable hydrogel. One 
limitation of this method is that the scanner only provides a 3D rendering of the external features 
of the rat head with no details provided regarding the underlying structure or composition. This 
can affect the apparent size of the measurements. 
 
A 
 
B 
 
Fig. 1. (A) Rat head immediately after implantation surgery with sutures (red arrow). The 
implanted gel is indicated by a white arrow.  (B) The swelling of an implanted gel over time is 
measured by laser scanning. The pink arrow shows a laser scanning line.  
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 After 6 weeks of expansion, the rats were sacrificed and the expanders were removed. 
Histology was performed on tissue cross sections of the calvarial periosteum and skin flap that 
had surrounded the hydrogel before removal. Grossly, a thin pseudocapsule remained with the 
skin ellipse so that cross sections were easily made after formalin fixation. Initially this work was 
performed as a pilot study with 18 rats. As a control, commercially available Osmed™ 
expanders (Osmed Gmbh, Stuttgart, Germany) were also implanted above the rats’ skull. 
 
2.8. Histometric analysis 
 
 Immediately after harvesting, the tissue samples were fixed in a neutral 10% solution of 
formaldehyde in phosphate buffered saline at room temperature. Fixed tissues were cut into 2 
mm-thick sections, dehydrated and embedded in paraffin blocks according to laboratory standard 
procedures.  Four-micron sections from each tissue sample were stained with hematoxylin and 
eosin (H&E), or with Masson's trichrome stain according to standard protocols. 
 
 Sections stained with H&E were useful for identifying inflammatory cells and for locating 
phagocytic histiocytes (foam cells). Trichrome staining was helpful for studying vascularity, 
identifying residual fragments of hydrogel and measuring the capsule thickness. Residual 
hydrogels that are usually found in animal studies appear to be blisters or bubbles of faintly blue 
material pinched off from the main gel body by fibrous tissue of the capsule. These signs of 
retained hydrogel were, therefore, designated as “blebs.” These were scored as either absent or 
present.  
 
 Each histologic feature was graded by three examiners and discrepancies in scoring were 
resolved by conference review of the relevant sections at a multi-head microscope. Binary acute 
and chronic inflammation scores indicated either absence or presence of neutrophil or 
lymphocyte infiltration, respectively. The score was 0 if no more than 3 of the relevant 
inflammatory cells were found in the section. Foam cells were assumed to represent 
phagocytosis of foreign material near the hydrogel. Scores were 0 for no foam cells, 1 for fewer 
than 3 foam cells, 2 for 4~6 foam cells, 3 for clusters of foam cells, and 4 for groups of foam 
cells seen at low power adjacent to the capsule. Thickness of the fibrous capsule was measured at 
an area where there was no distortion by oblique tissue orientation or partial thickness 
sectioning. Scores for capsule were 0 for no fibrous capsule, 1 for capsule thickness ≤20 µm, 2 
for 20~50 µm, 3 for 50~100 µm, and 4 for ≥100 µm. Vascularity was assumed to represent either 
native dermal capillaries or reparative neo-vessels generated by angiogenic cytokines related to 
surgery or the hydrogel implant. Since these neo-vessels are larger, have no pericytes and are 
often congested, they are more easily seen at low magnification than normal resident capillaries. 
Grades for vascularity, therefore, were 0 for small capillaries seen only with the high power 
objective, 1 for scattered, congested capillaries visible with 10x objective, 2 for increased 
numbers and clusters of capillaries, 3 for large, irregular, thin-walled venule-like neo-vessels, 
and 4 for crowded thin-walled vessels with stromal edema surrounding the hydrogel capsule. 
 
3. Results 
 
3.1. Synthesis and characterization of reshapable hydrogels 
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 The new reshapable hydrogel expander developed in this research consists of hydrophilic 
poly(ethylene glycol) (PEG) block and hydrophobic poly(lactide-co-glycolide) (PLGA) that 
controls the swelling rate. As previously reported [31, 32], the swelling of the whole polymer 
matrix is temporarily retarded by the hydrophobic polyester regions, which results in a lag time 
before the expander starts swelling.  Such a lag time is designed for the tissue to heal after 
surgical implantation of the hydrogel.   
 
 A series of custom acrylate activated macromers were synthesized as listed in Table 1.  The 
L:G ratio of PLGA was 50:50, and the molecular weights of PLGA and PEG blocks were also 
varied from 333 to 7,500 and from 1,000 to 1,500, respectively. M4 in Table 1 was generated by 
modification of PLGA with acryloyl chloride. 
 
Table 1. Acrylate activated triblock PLGA-PEG-PLGA copolymers. 
Macromer Code Description 
M1 PLGA-PEG-PLGA diacrylate (L:G 50:50)   333-1500-333 Da   
M2 PLGA-PEG-PLGA diacrylate (L:G 50:50) 5000-1000-5000 Da   
M3 PLGA-PEG-PLGA diacrylate (L:G 50:50) 7500-1000-7500 Da  
M4 PLGA acrylate (L:G 50:50)   20,000 Da   
M5 PLGA-PEG-PLGA diacrylate (L:G 80:20) 492-1500-492 Da  
 
 As described, this series of custom crosslinkers were first synthesized to prepare delayed 
swelling hydrogels. The crosslinkers were made by ring opening polymerization followed by 
reacting with acryloyl chloride to attach reactive vinyl groups. Fig. 2 shows an NMR spectrum 
of a custom made PLGA-PEG-PLGA diacrylate crosslinker, and peak assignments of CDCl3 
solvent, acrylate, lactide, glycolide, terminal ethylene glycol, polymer ethylene glycol, and 
lactide methyl groups. 
 
 
Peak Assignments 
CDCl3 solvent: 7.3 ppm. 
Acrylate (-CH=CH2): triplet 5.9, 
6.3, and 6.6 ppm. 
Lactide (CCH3HCOO): 5.2 ppm. 
Glycolide (CH2COO): 4.8 ppm. 
Terminal ethylene glycol 
(CH2CHOH): 4.3 ppm. 
Polymer ethylene glycol 
(CH2CH2O): 3.6 ppm. 
Lactide methyl (CCH3HCOO): 
1.7 ppm 
Fig. 2. NMR analysis of a synthesized triblock PLGA-PEG-PLGA diacrylate with block 
molecular weights of 5,000-1,000-5,000 (M2 in Table 1).   
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 The acrylate content was quantified by proton counting. The sum integration of the peaks 
from 5.9-6.6 ppm (3.72 in total) is attributed to acrylate vinyl units (3H). This was comparing 
with the peak integration at 3.6 ppm (52.69) which corresponds to poly(ethylene glycol) (4H per 
ethylene glycol unit). According to the manufacturer’s information, the PEG has an average of 
approximately 22.7 repeating units (~1000 Da). By comparing the integrations, the acrylate 
content was quantified as 2.1 acrylates/chain. It is not exactly 2.0, due to dispersity of the 
polymer chains. It is, however, suitably acrylate activated to serve as a macromer. 
 
 FTIR results also confirmed 
the presence of ester, ether, and 
acrylate moieties as expected. In 
the FTIR spectra, strong bands 
were observed at ~1750 cm-1 
due to ester bonds. Smaller 
peaks were seen around 1680 
cm-1 indicating alkene (C=C) 
stretching of acrylates and in the 
3100 cm-1 region indicating 
alkenyl (C=C-H) stretching. 
There was also a strong C-O 
stretch band in the 1100 cm-1 
region from ether bonds of PEG 
as well as a band around 1200 
cm-1 from ester and acrylate C-O 
stretching [44-46]. An example 
FTIR spectrum is shown in Fig. 
3.  
 
 GPC was performed to measure the molecular weight of the synthesized macromer 
components by calibrating the chromatograms using known polystyrene standards. The exact 
molecular weight values obtained from GPC varied from lot-to-lot, but were generally in good 
accordance with the expected values based on nominal molecular weights. For example, M2 
(5000-1000-5000 Da) has a nominal overall molecular weight of 11,000 Da. Table 2 below 
shows GPC data from a series of lots of this material.  Typically, number average molecular 
weight tends to run low due to skewing by short-chain components, and weight average 
molecular weight tends to run higher due to skewing by high molecular weight components [47]. 
These data support a nominal molecular weight between these values. A ratio of these extreme 
values, the polydispersity index (PDI), gives an estimate of the molecular mass distribution or 
size heterogeneity index. As polymer chains approach uniform chain length, the PDI approaches 
unity (1.00).  The macromers listed in Table 1 were used to generate reshapable hydrogels of 
different properties, as shown in Table 3. The reactions were done in anhydrous DMSO at 
concentrations between 10-30% (w/v, total solids). 
  
 
 
 
Fig. 3. FTIR spectrum of PLGA-PEG-PLGA diacrylate 
(M2 in Table 1). 
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Table 2. GPC data from a series of different lots of M2. 
Lot# Molecular Weight PDI 
Number average (Da) Weight average (Da) 
1   9,180 18,848 2.05 
2   8,458 17,729 2.10 
3 10,276 15,792 1.54 
 
 
Table 3. Reshapable hydrogel formulations used in this research. 
Formulation Hydrogel composition (%(w/w) specified macromers)  
1 50.0% M1 + 50.0% PEGDA (700 Da) 
2 66.6% M5 + 33.3% PEGDA (700 Da) 
3 60.6% M2 + 30.3% PEGDA (700 Da)   + 9.1% M4 
4 70.2% M2 + 26.3% PEGDA (700 Da)   + 3.5% M4 
5 45.1% M2 + 48.4% PEGDA (700 Da)   + 6.4% M4    + 0.1% EGDMA 
6 60.5% M2 + 30.3% PEGDA (700 Da)   + 9.1% M4    + 0.1% EGDMA 
7 63.2% M2 + 31.6% PEGDA (700 Da)   + 4.8% M4    + 0.5% EGDMA 
  8* 60.6% M2 + 30.3% PEGDA (700 Da)   + 9.1% M4  
9 58.0% M3 + 29.0% PEGDA (700 Da)   + 8.7% M4    + 4.3% EGDMA 
10 69.9% M3 + 26.2% PEGDA (700 Da)                         + 3.8 % EGDMA 
11 60.7% M2   + 26.6% PEGDA (700 Da) + 8.4% M4    + 4.2% EGDMA  
12 40.0% M2 + 42.8% PEGDA (700 Da) + 17.2% M4    + 0.1% EGDMA 
13 39.3% M2 + 42.1% PEGDA (700 Da)   + 5.6% M4 + 12.9 % EGDMA 
Osmed Methyl methacrylate and N-vinylpyrrolidone copolymer (Periost Expander 0.45 
ml)  
*Dip coated with poly(N-vinylpyrrolidinone) (PVP) (55,000 Da).  
  
 
3.2. Swelling Rate 
 
 Each reshapable hydrogel was tested for its swelling rate and weight ratio profile by 
measuring the weight change at predetermined time points in PBS. Swelling of the monolithic 
hydrogels is assumed to be uniform along all axes (isotropic), and thus, changes in mass due to 
water absorption would be directly related to the change in size. An interesting feature to the 
swelling profile was observed upon varying the relative quantities of PEG and polyester content. 
Fig. 4-A shows a swelling profile of a reshapable hydrogel with a high PEG content. In the 
beginning, the swelling ratio was limited to about 10, followed by very slow swelling for about a 
week. The hydrogel started swelling faster and reached a peak swelling ratio of about 130 at Day 
14.  The rapid increase after 10 days is due to degradation of polyester crosslinks.  The sharp 
decrease after reaching the peak is due to dissolution of PEG molecules after degradation of 
PLGA crosslinks.   
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A 
 
B 
 
C 
 
D 
 
Fig. 4. In vitro swelling profile of Formulations 1 (A), 3 (B), 13 (N = 12) (C), and Osmed (D). 
Error bars show standard deviation. Unless otherwise specified, N = 3. 
 
 When the reshapable hydrogels were synthesized with a higher quantity of hydrophobic 
PLGA, the overall swelling decreased. The swelling ratios of Formulation 3 in Fig. 4-B are an 
order of magnitude smaller than those in Fig. 4-A. The swelling continued at a slow rate, 
reaching the swelling ratio of 5 after 60 days. For the low PLGA content expanders (e.g., 
Formulation 1), the degradable hydrophobic chains create temporary crosslinks which hold the 
structure in place and do not allow the gel expansion until they are cleaved [31]. The material as 
a whole is highly hydrophilic and once the crosslinks are broken there is extensive swelling prior 
to complete dissolution. For the high PLGA content expanders (e.g., Formulation 3), expansion 
is controlled by the presence of crosslinks and the overall increase in hydrophobicity from 
PLGA. In other prototypes, additional permanent crosslinks were generated by the addition of 
ethylene glycol dimethacrylate (EGDMA) to the reaction (e.g., Formulation 13). This resulted in 
a specific maximum swelling ratio based on non-degradable crosslinks. This limit in the 
maximum swelling allows easy control of the final swelling ratio by the permanent crosslinks 
(Fig 4-C). It is noted that the plateau swelling ratio of 1.8 was obtained after 30 days. In about 2 
weeks, the swelling ratio was around 1.4, indicating 12% expansion in each direction. Fig. 4-D 
shows the swelling kinetics of the Osmed expander which relies on a hydrogel wrapped inside of 
a silicone rubber membrane. Small holes in the membrane allow for controlled access to fluids, 
and the maximum swelling is controlled by the expansion of the silicone rubber membrane. The 
swelling profile of an Osmed expander shows that the plateau swelling ratio of 3 was reached in 
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about 2 weeks. This is a 44% increase in size in all directions. In a confined environment, a 
hydrogel with 44% expansion in one dimension may exert more pressure than that with 12% 
expansion in one dimension. Such a difference may be critical in certain applications, e.g., 
swelling of a hydrogel implanted under tissue with suturing. One critical difference between 
reshapable hydrogel formulations made in this study and the Osmed expander is that the swelling 
of Osmed is controlled by the external silicone rubber membrane, while the reshapable hydrogels 
synthesized in this study is controlled by the hydrogel itself without any wrapping membrane 
[18, 48]. Thus, the hydrogel expanders prepared in this study can be reshaped in size by cutting 
and the swelling kinetics can be controlled by the reshapable hydrogel composition and not by 
the membrane coating. 
 
3.3. Mechanical Properties/Swelling Pressure 
 
 The dry hydrogel for tissue expander applications needs to have mechanical properties 
allowing for reshaping prior to emplacement. Elastic deformability makes it possible for 
surgeons to modify the size and shape of the dry hydrogel at the time of insertion. These 
properties were assayed by compressing discs of the reshapable hydrogel expander using the 
TA.XTplus mechanical tester. Results from this testing are shown in Table 4. Each hydrogel 
example used in the study displayed similar dry mechanical properties suitable for shape 
modification by typical steel blades during the implantation procedure. 
 
 
Table 4. Mechanical properties of dry reshapable hydrogels (average ± standard deviation). 
Formulation Elastic modulus (kPa) Stress Relaxation (%) Swelling pressure (mmHg) 
1    2 ± 0.5 (n=3) 94 ± 0.3 (n=3)  450 ± 87 (n=3) 
2 2 ± 1 (n=3) 95 ± 1 (n = 3) 1,614 ± 560 (n=3) 
13 10 ± 6 (n=12) 52 ± 5 (n=12)      794 ± 362 (n=12) 
 
 Another key property for tissue expansion applications is the swelling pressure which results 
from the expanding hydrogel encountering changing physical constraints of the surrounding 
tissue. Previous research has established a range from 25 to 235 mmHg as an appropriate 
pressure to elicit tissue expansion [18, 49, 50]. Thus, tissue expanders need to be capable of 
generating at least 25 mmHg of pressure to expand tissues. To test the swelling pressure, 
expanders were swollen in an acidified saline immersion between the mechanical tester probe 
and the bottom of a vial. To expedite the degradation of PLGA crosslinkers, the pH of the 
physiological saline solution was lowered by adding hydrochloric acid (0.154 M HCl, pH ~ 0.8-
1.0) [51, 52]. In this test system the reshapable hydrogel swelling pressures were 2- to 7-fold 
greater than 235 mmHg, the upper limit of the reported appropriate pressure for tissue expansion. 
The in vitro swelling test indicated that the swelling pressure of the reshapable hydrogels was 
adequate to expand tissue, and it was anticipated that lower ionic strength and competing tissue 
oncotic pressure would limit the swelling pressure in vivo. However, when the expansion 
pressure exceeds 235 mmHg it can compress tissue arterioles and reduce blood circulation to the 
flap. Thus, the swelling pressure alone would reduce blood perfusion [53].  The swelling 
pressures in Table 4, however, were obtained in an accelerated PLGA degradation condition. 
Thus, in in vivo applications, the delayed, slow swelling is not expected to cause the problem.  
The in vivo tests below address this point. 
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3.4. Mechanical Strength post-degradation 
 
 Clinical use of the expander relies on the fact that it is a temporary implant. After the 
expander has generated a flap of tissue, it must be removed to make space for the subsequent 
permanent implant or to use the tissue for closure procedures. The test methodology was adapted 
from techniques used in the food industry for semi-solid and hydrogel type materials [53-56]. In 
this case, the force required to press a ¼ inch steel ball through the fully swollen expander was 
divided by the expander thickness to generate a quantifiable description of the reshapable 
hydrogels post-swelling mechanical strength (Table 5).  
 
 
Table 5. End-strength of swollen hydrogels after 2-month incubation at 37 °C in PBS. Data 
shown as average ± standard deviation. 
Formulation End-Strength 
1 Dissolves to liquid after 16 days (n=3) 
2 0.05 ± 0.05 N/mm (n=3) 
9 0.02 ± 0.003 N/mm (n=2) 
10 0.18 ± 0.11 N/mm (n=2) 
11 0.07 N/mm (n=1) 
12 0.42 N/mm (n=1) 
13 1.45 ± 1.30 N/mm (n=3) 
 
 Formulation 1 hydrogel without a non-degradable crosslinker, EGDMA, did not maintain the 
gel shape and dissolved into a liquid after 16 days of incubation. All formulations in Table 5, 
except Formulation 1, contained EDGMA, and they maintained the hydrogel shape, although the 
end-strength varied greatly from 0.02 N/mm to 1.45 N/mm.  The improved end-strength proved 
to be critical for functioning as a tissue expander as described in the in vivo data below. 
  
3.5. In Vivo Test 
 
 Reshapable hydrogels with acceptable dry properties, swelling pressure, swelling rate and 
strength after swelling proceeded to in vivo testing in a rat model. For this test, expanders were 
cut into discs (~2-3 mm thick x 3-5 mm diameter). These discs were implanted with full-
thickness in the rat scalp just above the periosteum of calvarium between the ears. The wound 
was closed with interrupted sutures. During the study, no rat showed any symptom of systemic 
toxicity, such as weight loss, loss of appetite, or behavioral changes. One rat implanted with 
formulation 12 had a local infection, which led to sacrifice and exclusion from the study. One rat 
displayed a non-expander related skin ulceration caused by rubbing his head on the cage top. 
This accidental trauma was remedied by moving the food supply to the bottom of the cage. The 
ulcer soon healed and the animal was included in the study. Other than these complications, none 
of the animals displayed signs of local reaction, such as inflammation, necrosis, dehiscence, or 
peri-orbital edema.  Each rat’s head was scanned using a Faro-arm scanner to render a 3D image 
of the expander. Three-dimensional (3D) image analysis was performed using Geomagic Qualify 
software to determine volume and surface area of the expanded portion (Fig. 5). This limitation 
complicates the precise measurement of the expander under the tissue as the rendering does not 
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indicate the difference between expander, flesh, and skull. For this reason, over the course of 
healing and tissue relaxation, the size of the expander tends to be underestimated especially 
under late-stage expansion. Despite this limitation, the technique still provides a relative estimate 
of total expansion. 
 
 
A 
 
B 
 
Fig. 5. A side profile view of a rat with an expander implanted in the head (A) and an image of 
3D scan data from rat used in 3D analysis testing (B).  The red arrow indicates the location of the 
implanted expander. 
 
 
 Initially, a pilot study was performed using six of the prototype expanders in 18 rats. The 
volume change was calculated from the Faro data based on the volume at initial insertion 
according to the equation: 
∆𝑉𝑡 =
𝑉𝑡
𝑉𝑖
 
where Vi represents the volume of the expander right after initial insertion and Vt represents the 
volume of the expander at the respective time point. The swelling change was calculated at 2, 14, 
and 42 days of expansion as shown in Table 6 below. On Day 2, post-operative swelling and 
hemorrhage had resolved on most animals.  Tissue expander hydrogels continued to swell to Day 
14, except Formulation 8. Formulations 3, 4, and 5 showed reduced size at Day 42, while 
Formulation 6 kept swelling. Comparison of Formulations 3~6 in Table 3 indicates that 
Formulation 6 has non-degradable crosslinker EGDMA and a higher amount of PLGA than 
others. The presence of a higher amount of hydrophobic PLGA is thought to slow down the 
crosslinker degradation, resulting in continuous swelling.  The plateau swelling by Formulation 7 
is likely due to the higher (0.5%) concentration of EGDMA, a non-degradable crosslinker. 
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Table 6. The in vivo volume swelling change (∆Vt) as measured by Faro
® arm. (Average ± 
standard deviation (*N = 2, otherwise N=3) 
Formulation 
Swelling (Average volume change) 
Day 2 Day 15 Day 42 
3  1.37 ± 0.27* 1.78 ± 0.47* 1.65 ± 0.02* 
4 1.50 ± 0.30 2.42 ± 0.44 1.79 ± 0.40 
5 1.65 ± 0.09 2.22 ± 0.65 1.89 ± 0.28 
6 1.48 ± 0.28 2.33 ± 0.35 2.87 ± 1.01 
7 1.49 ± 0.47 1.75 ± 0.61 1.66 ± 0.08 
8 1.36 ± 0.20 1.08 ± 0.85 1.74 ± 1.34 
  
 
 Upon necropsy, the expanded gels were observed to have induced the formation of a thin, but 
discrete, fibrous capsule, attached to reflected skin, a process which is common for implants 
[57]. Fig. 6-A shows an example of fibrous capsule (as indicated by yellow arrows) surrounding 
a tissue expander hydrogel. Fig. 6-B shows small resorption of bone surrounding the swollen 
hydrogel that occurs by pressure of an expanding gel. This happens with all tissue expanders 
[58]. Some reshapable hydrogels in this pilot study showed mechanically weak structure which 
became a soft mush when the fibrous capsules were opened. Since this softening appeared 
related to crosslinking density, subsequent in vivo studies focused on more extensively 
crosslinked formulations. 
 
 
A 
 
B 
 
Fig. 6. (A) A hydrogel tissue expander (Formulation 8 in Table 3) wrapped around by a formed 
fibrous capsule (yellow arrows) after 6 weeks of insersion.  (B) Another tissue exander showing 
slight resorotion of bone (blue arrows) due to expanding gel. 
 
 
 The next study, a 72-rat study, focused on expansion and end-condition properties. An 
additional 5 prototypes were generated and tested in 6 rats per each expander formulation. For 
each test group, three rats were sacrificed after 4 weeks and the remaining after 6 weeks. As a 
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control, 3 commercially purchased Osmed expanders were implanted and tested in the same 
manner as the hydrogel expanders over 6 weeks. Similar to the pilot study, Faro scans were 
collected and the volume change at each time point calculated. Fig. 7 shows volume expansion 
changes for selected prototypes and the Osmed control. Even though a silicone shell covered the 
core hydrogel in the Osmed formulation, it still swells very fast in the first few days. This fast 
swelling was tolerated in the current model, but would present problems for stiffer or slower 
healing tissues. The slow swelling followed by maintaining a certain swollen state turns out to be 
important for allowing the sutured area to heal and maintain the expanded space. 
 
 
Fig. 7. In vivo volume expansion profiles of Osmed (Blue diamond), Formulation 5 (red square), 
Formulation 12 (green triangle) and Formulation 13 (purple x).  (Average ± standard deviation). 
 
 
 The Faro scan data primarily provided basic monitoring of the expander. Clinical 
functionality is the true result from these studies. No expanders presented signs of necrosis or 
expulsion indicating that the swelling rate was appropriate. Additionally, the end-condition of the 
reshapable hydrogel is a critical functional parameter for usability. Notably, higher crosslinked 
formulations presented a higher capacity for removal as a single piece. Fig. 8 displays an image 
series which relates to this. Of the second prototype series, only Formulation 13 allowed for 
consistent removal as a single piece without crumbling or cracking. Fig. 8-A shows the 
implanted hydrogel swollen over time as shown in Fig. 7. Fig. 8-B shows removal of a swollen 
hydrogel in its intact form. This is one unique mechanical property of the reshapable hydrogel 
that allows for easy removal after tissue expansion has been made. The left hydrogel in Fig. 8-C 
is in the fully swollen state of the same hydrogel before implantation on the right. If the hydrogel 
does not have enough mechanical strength after swelling, it easily breaks into big pieces, as 
shown in Fig. 8-D. Even though the weak hydrogel broke during removal through incised skin, 
there were only a few big pieces which were still easy to remove.    
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A 
 
B 
 
C 
 
D 
 
 
 Fig. 8. Swelling of Formulation 13 for 6 weeks on a rat head (A).  Removal of the swollen 
Formulation 13 after incision through the skin (B). Comparison of the recovered Formulation 13 
(left) and the original hydrogel before implantation (right) (C). Removal of the swollen 
Formulation 12 from tissue for comparison (D). 
 
 
3.6. Histological analysis 
 
 In addition to notation of expansion and removal conditions, histology was performed on 
each rat sacrificed at 4 and 6 weeks to determine the effects of reshapable hydrogel formulations 
on tissue. After fixation in formalin, the samples were transverse sectioned at 1 mm intervals, 
embedded in paraffin, thin sectioned at 4 µm thickness and stained with hematoxylin and eosin 
or Masson’s trichrome stain (Fig 9). The prepared samples were scored by an experienced 
histologist for the presence of hydrogel blebs, fibrous capsule thickness, chronic inflammation, 
vascularity, foam cells, and acute inflammation.   
 
 Chi-square tests were performed to determine if there were any significant differences among 
groups for blebs, chronic inflammation, or acute inflammation. Mantel-Haenszel tests for 
ordered categorical responses were performed to determine if there were any significant 
differences among groups for fibrous capsule, vascularity, or foam cell scores. There were no 
statistically significant differences among groups for blebs (p=0.17), fibrous capsule (p=0.30), 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
chronic inflammation (p=0.30), foam cells (p=0.06) or acute inflammation (p=1.00). This 
indicated that the formulations had biocompatibility at least as good as the current, clinical 
Osmed material. Formulation 13 had significantly higher vascularity scores than other groups, 
indicating superior revascularization of the skin flap at 6 weeks. The formation of the 
macroscopic capsule was suitable for aiding removal of the piece by allowing the hydrogel to 
slide easily out of the distinct capsule. The capsule and the hydrogel upon removal at necropsy 
are shown in Fig. 10. 
 
 
 
Fig. 9.  Trichrome stain of the inner fibrous 
capsule (blue arrow) by skin during rat study.  
A capsule consistently formed around the 
expanded reshapable hydrogel. 
Fig. 10. Hydrogel (yellow arrow) enveloped in 
fibrous capsule (green dotted arrow) at 
removal. 
 
 
4. DISCUSSION 
 
 One way to eliminate the injection issue is to use a hydrogel expander which swells by 
absorption of surrounding bodily fluids. In this system, it is osmotic pressure rather than external 
injection controlling the expander swelling. Such an osmotic system named OsmedTM was 
developed using a matrix of methyl methacrylate and vinylpyrrolidone.  There is no delay factor 
or crosslinked mechanical strengthening with this hydrogel. Rather, it is encased in a silicone 
shell with select-sized pores to control bodily fluid influx and to stabilize the matrix for complete 
removal [18, 59, 60]. This external membrane constrains the size and shape for such expanders, 
especially in small spaces or for specialized applications. A novel expander in which the 
swelling delay factor is built into the polymer itself and the dry properties allow it to be cut by 
the surgeon at time of emplacement would overcome these limitations. Such a device could fit 
the patient rather than forcing the patient to fit the pre-sized expander.   
 
 Initial work toward this goal found that the expansion rate could be controlled by creating a 
system wherein the crosslinks are held in place by PLGA which is hydrolytically degradable 
allowing for expansion of the hydrogel after a predetermined delay (Fig. 4-A). However, this 
system did not have the properties desirable for surgical applications. First, the expansion 
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volume was over 25-fold higher than expedient for surgical applications, which require only 2-to 
5-fold expansion. Second, the expander became soft and liquid after the crosslinks degraded 
making removal impractical. The simple addition of permanent crosslinks using non-degradable 
(within the usage time scale) EGDMA allowed the expanders to maintain form and have residual 
strength after the degradable crosslinks had cleaved (Fig. 4-B). Additionally, the incorporation of 
higher molecular weight PLGA components into the reaction mix allows for dual delay 
mechanisms in which the delay factor is controlled both by the breaking of crosslinks and by the 
shifting hydrophilic/hydrophobic mix of the system. This improves hydrophilicity upon polymer 
degradation and buffers the hydrophobic expansion pressure. This is evident in the decreased 
swelling caused by the addition of PLGA-acrylate which increases the hydrophobicity of the gel 
without serving as a crosslink. In vitro testing determined the formulations to have suitable 
mechanical properties and swelling pressure for shape-ability, adequate tissue expansion, and 
complete removal after expansion. 
 
 The mechanical properties, as well as swelling and other properties, are a result of the 
composition and crosslinking of the hydrogels. The PEG block is more flexible than the PLGA 
block, and the formulations with high relative contents of PEG (Formulations 1 and 2) have a 
lower initial elastic modulus. The relaxation (delayed viscous deformation) for the formulations 
with shorter distances between the crosslinks reflects a higher value as these formulations have 
very limited capacity for the chains to move relative to each other due to denser crosslinking. All 
formulations shown, however, had suitable flexibility for reshaping. Some formulations 
generated with such high crosslinking density exhibited mechanically brittle properties and 
shattered upon attempts to cut [61]. These formulations were not included in the study. 
 
 In vivo model testing indicated that these formulations were well suited for skin application. 
Throughout the study, only a single event of localized infection was noted. No other localized or 
systemic toxicity was found. No mechanically-related flap damage such as incision dehiscence, 
tissue blanching, or necrosis was noted. A key usability feature of the developed expander is its 
removability. In vivo model testing indicated this is an important requirement for the tissue 
expanding usefulness of the material. By improving the crosslinking density, a formulation was 
found (Formulation 13) allowing for expander removal as a single piece. Another usability 
feature is the quality of the expanded tissue. For the tissue to have surgical value, it must be well 
perfused with oxygenated blood. By maintaining a moderate expansion profile, Formulation 13 
allowed for the formation of highly vascularized tissue despite a 2-fold increase in volume under 
the flap. 
 
5. CONCLUSION 
 
 To provide for osmotically powered expansion, without requiring an external membrane, the 
swelling pressure and rate properties must be built into the hydrogel itself. Such a hydrogel can 
be generated by use of chemically crosslinked hydrophilic polyether (polyethylene glycol) and 
hydrophobic polyester (PLGA) wherein the degradation of the PLGA controls the swelling rate. 
Mechanical properties are maintained by the incorporation of permanent crosslinks of EGDMA 
to prevent total dissolution of the reshapable hydrogel and to maintain structural integrity in the 
swollen state. This cohesiveness of the swollen gel allows for surgical removal as one piece 
without residue in the tissue. Reshapable hydrogels generated in this manner have proven their 
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surgical relevancy in an animal model by the successful expansion of well-vascularized skin in a 
rat skin model. This technology holds promise for the development of reshapable tissue 
expanders for clinical use, particularly in physically constrained environments where ability to 
adjust the expander’s size and shape is desirable.    
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